Evidence Hub

Global, regional, and national burden of acute myeloid leukemia attributable to tobacco from 1990 to 2021, with future forecasts to 2050: A secondary dataset analysis of the Global Burden of Disease 2021 study

Zhang J, Zhao L, Chao Y, Zhang Z, Guo J

Tobacco induced diseases, 2026

100,000 participants

Abstract

Introduction: Acute myeloid leukemia (AML) is a major public health problem. However, the epidemiological pattern of the burden of AML attributable to tobacco globally remains unclear. This study aimed to characterize the global, regional, and national burden of AML attributable to tobacco from 1990 to 2021 and to forecast it to 2050.

Methods: Data were sourced from the Global Burden of Disease (GBD) study 2021, and secondary dataset analysis was used in the present research. Age-standardized rates of tobacco-attributable AML deaths and disability-adjusted life years (DALYs) were analyzed, with estimated annual percentage change (EAPC) calculated. Age-period-cohort (APC) analysis was performed to quantify the age, period, and birth cohort effects on AML attributable to tobacco. A Bayesian APC model was subsequently us ed to project the disease burden of attributable to tobacco between 2022 and 2050.

Results: From 1990 to 2021, the burden of AML attributable to tobacco globally presented downward trends. The age-standardized death rate (ASDR) decreased from 0.214 [95% uncertainty interval (UI): 0.08-0.35] per 100000 people in 1990 to 0.176 (95% UI: 0.062-0.307) per 100000 people in 2021. The high sociodemographic index (SDI) regions had the highest ASDR and age-standardized DALYs rate for AML attributable to tobacco in 2021. The greatest burden of AML attributable to tobacco was the age group of 70-74 years among the risk factors of AML; tobacco shared at 11.5% of global…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 100,000 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free